MedTrace Logo

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

NCT02022540 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-09-28

No results posted yet for this study

Summary

The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with active, subfoveal choroidal neovascularization associated with neovascular Age-Related Macular Degeneration (AMD).

Conditions

  • Age-Related Macular Degeneration (AMD)

Interventions

DRUG

PAN-90806 Ophthalmic Solution

DRUG

Lucentis

Sponsors & Collaborators

  • PanOptica, Inc.

    lead INDUSTRY

Principal Investigators

  • Martin Wax, M.D. · PanOptica, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-03-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02022540 on ClinicalTrials.gov